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Abstract
Background: The incidence of melanoma among those of an Asian ethnicity is lower 
than in Caucasians; few large‐scale Asian studies that include follow‐up data have 
been reported.
Objectives: To investigate the clinical characteristics of Japanese patients with mela-
noma and to evaluate the prognostic factors.
Methods: Detailed patient information was collected from the database of Japanese 
Melanoma Study Group of the Japanese Skin Cancer Society. The American Joint 
Committee on Cancer seventh Edition system was used for TNM classification. The 
Kaplan‐Meier method and Cox proportional hazards model were used to estimate the 
impact of clinical and histological parameters on disease‐specific survival in patients 
with invasive melanoma.
Results: In total, 4594 patients were included in this analysis. The most common 
clinical type was acral lentiginous melanoma (40.4%) followed by superficial spread-
ing melanoma (20.5%), nodular melanoma (10.0%), mucosal melanoma (9.5%), and 
lentigo maligna melanoma (8.1%). The 5‐year disease‐specific survival for each stage 
was as follows: IA = 98.0%, IB = 93.9%, IIA = 94.8%, IIB = 82.4%, IIC = 71.8%, 
IIIA = 75.0%, IIIB = 61.3%, IIIC = 41.7%, and IV = 17.7%. Although multivariate 
analysis showed that clinical classifications were not associated with survival across 
all stages, acral type was an independent poor prognostic factor in stage IIIA.
Conclusions: Our study revealed the characteristics of melanoma in the Japanese 
population. The 5‐year disease‐specific survival of each stage showed a similar trend 
to that of Caucasians. While clinical classification was not associated with survival in 
any stages, acral type was associated with poor survival in stage IIIA. Our result 
might indicate the aggressiveness of acral type in certain populations.
K E Y W O R D S
acral, Asian, Epidemiology, Japanese, Melanoma, mucosal
1 |  INTRODUCTION
In Japan, melanoma is classified as “rare cancer,” but 
the precise melanoma incidence in Japan has not been 
well investigated. Analysis of the Hospital Based Cancer 
Registries in Japan revealed the crude annual incidence 
of melanoma to be 1.75 per 100 000 people1; whereas 
the data from the World Health Organization showed the 
incidence of melanoma in Japan to be between 0.3 and 
0.8 per 100 000 people (male: 0.3‐0.8; female: 0.4‐0.6).2 
According to the Surveillance, Epidemiology, and End 
Results Program (SEER) data, Asian and Pacific Islanders 
had an annual incidence of 1.68 melanoma patients per 
100 000 people in contrast to that of non‐Hispanic Whites 
at 33.85 per 100 000 people,3 clearly showing the lower in-
cidence among Asians. Due to rarity of melanoma in Japan, 
it has been difficult to accumulate a large enough volume of 
patient data to conduct statistical analysis for investigating 
the unique characteristics of melanoma occurrence in the 
Japanese population.
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In 2001, Ishihara and colleagues reported the results of a 
nationwide survey to investigate melanoma incidence among 
Japanese patients.4 In the 2008 update of their study,5 a sur-
vival analysis of 2065 Japanese patients with melanoma, 
Ishihara and colleagues reported that the survival of acral 
lentiginous melanoma (ALM), which constituted 47% of their 
cohort, was statistically worse than that of superficial spread-
ing melanoma (SSM). However, their analysis was based on 
the Kaplan‐Meier method and log‐rank test and did not in-
clude multivariate analysis to compensate for other factors 
such as TNM status. Recently, molecular characterizations of 
ALM and mucosal melanoma (MCM) have shown that these 
clinical types are biologically distinct from the more common 
cutaneous melanomas.6,7 Some reports indicated that these 
two subtypes correlated with poor survival,8-11 while others 
have reported no correlation between clinical subtypes and 
prognosis.12,13
The recent development of immune checkpoint in-
hibitors has dramatically changed the treatment of mela-
noma.14-16 The response to immune checkpoint inhibitor 
among Japanese patients, however, has not been as favor-
able as that of Caucasians. For example, in Japanese clin-
ical trials of anti‐programmed death receptor‐1 (PD‐1) 
monoclonal antibody, the response ratios were reported to 
be 24.1%17 to 34.8%18 compared to 38%16 to 43.7%19 from 
studies conducted in the West, indicating that the Japanese 
patients with melanoma might have distinct PD‐L1 expres-
sion profiles.
In the current study, we collated and analyzed nationwide 
patient data (including data on survival) to investigate the de-
tails of melanoma among the Japanese population and per-
formed multivariate analyses to reveal the factors associated 
with survival by clinical type.
2 |  MATERIALS AND METHODS
The Committee of Statistical Survey of Skin Cancer 
Prognosis of the Japanese Skin Cancer Society are currently 
conducting a survey named the “Japanese Melanoma Study 
(JMS)” to accumulate data of patients with melanoma admit-
ted to 27 institutes in Japan since 2005 (See Table S1 for 
the collaborating institutes). The JMS currently has an on-
line patient information submission system and collaborat-
ing researchers access the web system at least once a year to 
submit new patient information and also update prognostic 
information and additional treatment performed after any re-
currence. The information of patient collected from 2005 to 
2017 is described in Table S1. In brief, age, sex, site of the 
primary tumor, clinical type, Breslow thickness, Clark level, 
regression, in‐transit/satellite, the American Joint Committee 
on Cancer (AJCC) seventh Edition TNM status, and fol-
low‐up data including type of recurrence and prognosis were 
included in the survey. All data pertaining to vital status 
and date of death were solely dependent on the investiga-
tor's reports. Patient follow‐up was conducted according 
to each doctor's decision, generally following guidelines 
published by the Japanese Skin Cancer Society or National 
Comprehensive Cancer Network (NCCN). In the Japanese 
guideline, the recommendation is as follows: at least every 
3 months for the first year and every 6 months for years 2‐5 
for stage I; every 3 months for the first 3 years and every 
6 months for years 4‐5 for stage II; and every month for the 
first 3 years and every 3 months for years 4‐5 for stage III 
or more. The follow‐up interval in NCCN is longer than the 
Japanese guideline. The follow‐up interval might be longer 
than the recommendation for elderly patients. This study was 
approved by the University of Tsukuba Hospital (59‐1) and 
the Japanese Dermatology Association.
Chi‐squared test was used to calculate P‐values of cat-
egorical difference. Kaplan‐Meier method was used to 
estimate survival curves and log‐rank test was used to cal-
culate the corresponding P‐values. Cox proportional haz-
ard model was used for both univariate and multivariate 
analysis to calculate factors associated with survival. First, 
we tested using a univariate analysis for factors that may 
associate with outcome. Next, in the multivariate analysis, 
we included factors that were shown to be statistically sig-
nificant in the univariate analysis. All statistical analysis 
was performed using free statistical analysis software R 
and P < 0.05 were considered as significant.
3 |  RESULTS
3.1 | Primary tumor
In total, data for 4594 patients were submitted to this sur-
vey. Background data are given in Table 1. The participants 
were 54.1% women and the average age of entire cohort was 
64.1 years. As shown in Table 2, the most common site of the 
primary tumor was the lower extremity (41.7%), followed by 
the upper extremity (20.2%), head and neck (14.2%), trunk 
(14.8%), and mucosa (9.5%). Of note, 44.7% of all melanoma 
occurred in hands and feet. Accordingly, the most common 
clinical type was ALM (40.4%), followed by SSM (20.5%), 
nodular melanoma (NM, 10.0%), mucosal melanoma (MCM, 
9.5%), and lentigo maligna melanoma (LMM, 8.1%).
Ulceration was present in 29.1% (n = 3629) of ALM, 
SSM, NM, and LMM tumors (four clinical types, Table 
3) and regression in 3.4%. Average Breslow thickness was 
3.73 mm with median of 2.20 mm. T classification based on 
AJCC seventh Edition in patients with complete pathologi-
cal staging (n = 3188) is as follows (Table 4): Tis = 23.6%, 
T1a = 16.2%, T1b = 2.4%, T2a = 10.1%, T2b = 3.3%, 
T3a = 8.7%, T3b = 9.3%, T4a = 7.1%, T4b = 18.1%, and 
not assessed = 1.3%. For reference, data of TNM status of 
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AJCC database20 are included in the Table 4. The distribu-
tion of the T subclass was significantly different compared 
with the AJCC database; the proportion of higher T status 
was more frequent in our study population.
3.2 | Lymph node status
Sentinel lymph node (SLN) biopsy was performed in 2076 
(65.1%) of patients with ALM, SSM, NM, or LMM and 481 
(23.1%) of them involved metastasis. Lymph node dissection 
without SLN biopsy was performed in 288 (9.0%) patients 
and 203 (70.5%) had tumor in the dissected nodes. Satellite 
or in‐transit metastasis was present in 151 (4.7%) patients. 
N classification is as follows (Table 4): N0 = 70.5%, 
N1a = 8.1%, N1b = 2.5%, N2a = 4.8%, N2b = 2.6%, 
N2c = 1.2%, N3 = 8.6%, and not assessed = 1.6%. For 
reference, TNM status of AJCC database20 was included 
in Table 4. The number of patients with N3 disease in our 
study population was significantly higher compared with the 
AJCC database.
3.3 | Distant metastasis
As described in Table 4, 198 (6.2%) patients with ALM, 
SSM, NM, and LMM had metastasis at diagnosis. Of 
them, 79 (40.0%) of those had elevated serum LDH levels 
(M1c).
3.4 | Pathological TNM staging and 5‐year 
disease‐specific survival
Data of pathological primary tumor and LN evaluation were 
available for 3438 patients, which included ALM, SSM, NM, 
LM, and MCM. Kaplan‐Meier (K‐M) plots for these five 
tumor types are shown in Figure 1A. Of these 3438 patients, 
follow‐up was lost for 465 of them during the study period. 
NM and MCM had significantly worse survival compared 
with other tumor types. There was no survival difference 
in between ALM and SSM. Next, after excluding patients 
with tumor in situ (Tis), we classified the remaining patients 
by localized, regional, and distant disease. K‐M plots for 
each category are shown in Figure 1B‐D. MCM showed a 
significantly lower survival in localized disease, but did not 
reach statistical significance in regional disease. Survival of 
patients with NM was statistically worse in both localized 
and regional disease. Interestingly, patients with ALM with 
regional disease showed poor survival compared with SSM.
Next the 3199 patients with ALM, SSM, NM, and LMM were 
classified according to the AJCC seventh Edition staging system 
T A B L E  1  Background of the study cohort
 Number % of Total
Total number 4594
Sex
Male 2107 45.9%
Female 2484 54.1%
Not described 3  
Age (years)
Average 64.1
Median 67.0
Range 2‐103
Pregnancy when diagnosed
Yes 16 0.6%
No 1557  
Not described 911  
Familial melanoma history
Yes 97 2.1%
No 2576  
Not described 1921  
History of other malignancy
Yes 361 7.9%
No 2475  
Not described 1758  
T A B L E  2  Site of the primary tumor and clinical type of the 
entire study cohort (n = 4594)
 Number Percent
Site of the primary
Head and neck 652 14.2%
Trunk 682 14.8%
Upper extremity
Hand 533 11.6% 20.2%
Other than hand 211 8.6%
Lower extremity
Foot 1522 33.1% 41.7%
Other than foot 394 8.6%
Mucosa 438 9.5%
Uveal 45 1.0%
Primary unknown 99 2.2%
Not described 41 0.9%
Clinical type
Acral lentiginous 1857 40.4%
Superficial spreading 942 20.5%
Nodular 458 10.0%
Lentigo maligna 372 8.1%
Mucosal melanoma 438 9.5%
Primary unknown 99 2.2%
Others/not described 383 9.3%
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and the result were as follows: stage 0 = 23.3%, IA = 15.2%, 
IB = 9.9%, IIA = 7.5%, IIB = 8.2%, IIC = 5.7%, IIIA = 5.7%, 
IIIB = 9.7%, IIIC = 8.7%, and IV = 6.2% (Table 5). Therefore, 
localized disease constituted 69.7%, regional disease 24.0%, 
and distant disease 6.2% of the total melanoma. The 5‐year dis-
ease‐specific survival (DSS) rate was as follows: IA = 98.0%, 
IB = 93.9%, IIA = 94.8%, IIB = 82.4%, IIC = 71.8%, 
IIIA = 75.0%, IIIB = 61.3%, IIIC = 41.7%, and IV = 17.7%. For 
reference, TNM status of AJCC database20 is included in Table 
5. The distribution of TNM stage was significantly different 
compared with AJCC. K‐M plots for each substage are shown 
in Figure 2A,B. Separation of survival curves within each stage 
was clear, indicating that the AJCC TNM staging system could 
clearly classify the melanoma of Japanese patients.
3.5 | Factors associated with survival
To investigate the factors associated with survival, only the 
patient data that included pathological classification and 
survival data were used. After excluding patients with Tis, 
2990 patients with invasive melanoma data were used for the 
further analysis. The result summary is shown in Table 6. 
All the factors in this table have been reported to associate 
with survival. Besides all the factors included in the univari-
ate analysis shown to be statistically significant prognostic 
factors, higher age (hazard ratio [HR]=1.01, P < 0.05), T 
status (HR = 1.552, P < 0.000001), N status (HR = 1.776, 
P < 0.000001), and distant metastasis (HR = 3.331, 
P < 0.000001) were shown to be independent prognostic fac-
tors for survival.
ALM and MCM have been reported to be associated with 
poor survival. We chose to focus on ALM, because MCM had 
already been shown to be a poor prognostic factor in the anal-
ysis using entire cohort (Figure 1). As shown in Figure 1A, no 
statistical difference was found only between ALM and SSM. 
Investigation of the survival curves of localized and regional dis-
ease classified by clinical type (Figure 1B), revealed that MCM 
and NM had worse survival compared with other types in lo-
calized disease (P < 0.05 and <0.0001, respectively). In regional 
disease (stage III), ALM and NM showed worse survival com-
pared with SSM (Figure 1C, both P < 0.05). There was no sta-
tistical difference between clinical types in stage IV (Figure 1D).
Next, each sub‐stage of stage III was further investigated. 
As shown in Figure 3A,C, stages IIIB and IIIC showed no sur-
vival difference between clinical types; however, survival of 
ALM was worse than that of SSM in stage IIIA. As T status 
and ALM were shown to be statistically significant (P < 0.05) 
in the univariate analysis, we included these factors in the mul-
tivariate analysis. As a result, multivariate analyses (Table 7) 
revealed that only ALM (HR = 2.80, P < 0.05) and T status 
(HR = 1.26, P < 0.01) were associated with poor survival in 
stage IIIA. We suspected the deviation of T and N status be-
tween ALM and SSM might explain the survival difference; 
however, the proportion of T1a‐4a and N1a‐2a in both groups 
was similar (data not shown). Therefore, no factor that could 
explain this survival difference apart from clinical type could 
be found. However, the number of patients in stage IIIA was 
small (ALM = 45, LMM = 7, NM = 36, and SSM = 92), and 
therefore, this difference might be just coincidental. Therefore, 
we need to accumulate more patient data to confirm the results.
In Japan, nivolumab treatment first became available in 
2014, thus, aside from those who patients involved in the 
clinical trials, we have only 4 years of experience with this 
treatment. As shown in Figure 4, there was a survival advan-
tage in patients with stage IV who received immune check-
point inhibitors and/or BRAF inhibitors (P < 0.001), clearly 
showing the benefit of these new drugs.
4 |  DISCUSSION
Our study revealed the unique characteristic of Japanese mel-
anoma patients. Notably, the most common clinical type was 
ALM (40.4%); in contrast, the proportion of ALM among 
non‐Hispanic whites in the SEER database was only 1.5%.3 
Therefore, 44.7% of all melanoma developed in the hand or foot. 
Furthermore, because 9.5% of those were MCM, ALM, and 
MCM together account for nearly half of all melanoma in Japan 
while SSM, the most common clinical type among Caucasian 
was only 20.5%. This fact clearly shows that the Japanese and 
Western melanoma patient populations differ greatly in terms 
T A B L E  3  Characteristics of primary tumor (n = 3629, only with 
four clinical classifications)
 Number % of Total
Ulceration
Yes 1055 29.1%
No 2429 66.9%
Not described 145 4.0%
Regression
Yes 125 3.4%
No 2026 55.8%
Not described 1218 40.8%
Clark's classification
1 649 17.9%
2 338 9.3%
3 409 11.3%
4 794 21.9%
5 414 11.4%
Not described 1023 28.2%
Breslow's thickness
Average 3.73 mm
Median 2.20 mm
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of the most common clinical types. This fact makes a differ-
ence in the proportion of cases with BRAF mutation; ALM and 
MCM are known to harbor the BRAF mutation far less than 
SSM.6 Indeed, Uhara and colleagues reported that among 171 
Japanese melanoma patients, overall BRAF mutation frequency 
was only 30.4% due to the low frequency of the mutation in 
ALM and MCM.21 In their study, only 12.5% of nail bed, 8.9% 
of palm or sole, and none of the MCM patients had the BRAF 
mutation.21 Thus, nearly 70% of advanced melanoma that occur 
in the Japanese population would have no benefit from BRAF 
inhibitor and this is a great disadvantage when compared with 
Western countries that have more (>50%)22 BRAF mutations.
Japanese melanoma patients tended to have considerably 
thicker primary tumors as shown in Table 4. The proportion 
of T4b in Japanese patients was 27.8%, whereas the AJCC 
database reported only 5.1%.20 Similarly, the proportion of 
patients with N3 was higher than in the AJCC database (Table 
4, 30.9% and 16.9%, respectively). As a result, the Japanese 
population has a greater proportion of higher stage mela-
noma; 27.4% of patients were stage III, compared with only 
8.6% reported in the AJCC database. These findings suggest 
that, because of its rarity, not many people in the general pub-
lic are aware of melanoma and consequently they tended not 
to visit a dermatologist at early stages of the disease.
When comparing the 5‐year survival in our study with the 
AJCC database20 (Table 5), we found a difference of nearly 
20% for stage IIC; 71.8% and 53%, respectively. Similarly, 
survival of stage IIA and IIB in our study was 93.9% and 
82.4%, respectively, compared to 82% (T2b), 79% (T3a), 68% 
(T3b), and 71% (T4a) in the AJCC database. On the other 
hand, substages of stage III were similar; IIIA, IIIB, and IIIC 
in our study were 78.8%, 62.2%, and 42.3%, respectively, 
compared to 78%, 59%, and 40% in the AJCC database. The 
reason for the discrepancy observed in stage II was unclear; 
T A B L E  4  TNM classification (AJCC 
2009, only with four clinical classifications)
 
Current study AJCC data P‐value
Number % of Total % Among patients with T1a‐T4b
T status
Tis 753 23.6%    
T1a 518 16.2% 21.6% 34.2% P < 0.000001 
chi‐square testT1b 75 2.4% 3.1% 8.6%
T2a 321 10.1% 13.4% 5.5%
T2b 105 3.3% 4.4% 23.6%
T3a 277 8.7% 11.6% 11.3%
T3b 298 9.3% 12.4% 7.8%
T4a 225 7.1% 9.4% 3.8%
T4b 576 18.1% 24.1% 5.1%
Not available 40 1.3%    
 Number % of Total % Among patients with N1a‐N3
N status
0 2249 70.5%    
N1a 259 8.1% 29.1% 44.3% P < 0.000001 
chi‐square testN1b 81 2.5% 9.1% 4.7%
N2a 154 4.8% 17.3% 17.4%
N2b 82 2.6% 9.2% 4.6%
N2c 38 1.2% 4.3% 12.1%
N3 275 8.6% 30.9% 16.9%
Not available 50 1.6%    
 Number % of Total    
M status
0 2990 93.8% 6.2%   
M1 46 1.4%   
M1a 43 1.3%   
M1b 79 2.5%   
M1c 30 0.9%   
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however, recently published data in which the same AJCC 
database was classified using the new eighth Edition clas-
sification system23 showed similar survival outcomes com-
pared to our results: 5‐year survival for IIA, IIB, and IIC were 
98%, 87%, and 82%, respectively. In this new AJCC database 
analysis, the authors excluded those patients recruited before 
the SLN biopsy method for classifying stage II disease was 
introduced, which suggest that the participants with stage II 
melanoma included in the seventh Edition classification may 
have included a considerable number of patients with occult 
LN metastasis.
In this study, we identified that (independent of TNM sta-
tus) higher age and specific clinical types (NM and MCM) 
were associated with poor survival as a poor prognostic fac-
tor (Table 6). This result confirms previous reports in which 
these factors were identified as being associated with poor 
outcome.3,8,9 ALM was not associated with survival across 
the entire cohort; however, regarding stage III, there was 
significant survival disadvantage for patients with ALM and 
NM compared with SSM (Figure 1C). Interestingly, survival 
curves of stage IIIA ALM were significantly worse than that 
of SSM, whereas no survival difference was found in stage 
F I G U R E  1  Kaplan‐Meier plots for 
patients classified according to the AJCC 
version seventh TNM classification system. 
Only patients with four clinical types 
(ALM, SSM, LMM, and NM) and have 
pathological diagnosis were included in 
this analysis. Survival curves for (A) all 
stages; (B) Stages I and II; (C) Stage III; 
and (D) Stage IV. * P < 0.05, ** P < 0.01, 
*** P < 0.001
T A B L E  5  Pathological TNM classification (AJCC seventh edition, only with four clinical classifications)
Stage
Number % of Total % Among patients without Tis 5‐Year DSS rate (%)
Current study AJCC data P‐value Current study AJCC data
0 743 23.3%    99.6%  
IA 483 15.2% 19.8% 24.5% P < 0.000 001 
chi‐square test
98.0% 97%
IB 316 9.9% 12.9% 23.1% 93.9% 94%(T1b)/91%(T3a)
IIA 238 7.5% 9.7% 12.0% 94.8% 82%(T2b)/79%(T3a)
IIB 260 8.2% 10.6% 8.4% 82.4% 68%(T3b)/71%(T4a)
IIC 182 5.7% 7.4% 3.6% 71.8% 53%
IIIA 181 5.7% 7.4% 3.1% 75.0% 78%
IIIB 309 9.7% 12.6% 3.6% 61.3% 59%
IIIC 278 8.7% 11.4% 1.9% 41.7% 40%
IV 198 6.2% 8.1% 19.8% 17.7% 14%
Total 3188 100%    
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IIIB and IIIC (Figure 3B,C). Because there was no difference 
regarding T and N subclass frequency in ALM and SSM, 
ALM itself may have led to worse prognosis in the early 
stages of lymphatic spread. Further accumulation of stage 
IIIA patient data is required to confirm this result and to re-
veal the cause of this difference in prognosis.
As described above, the chances of ALM having BRAF 
mutation are very low; therefore, immune checkpoint inhibitors 
should be the most appropriate treatment for advanced ALM. 
However, the response ratio of Japanese melanoma patients 
to immune checkpoint inhibitors tended to be lower than that 
of patients in Western countries.16-19 A South Korean study (a 
country with a population of a similar ethnical background to 
Japan) comprised 45.9% ALM and 24.3% MCM diagnoses, re-
ported that only 10.8% of the patients responded to anti‐PD‐1 
treatment.24 In our previous retrospective study of 45 patients 
with ALM and MCM treated at our institute, the response rate 
to anti‐PD‐1 treatment was 12.5% and 25%, respectively.25 This 
study suggested that while the use of anti‐PD‐1 therapy for ALM 
or MCM did elongate survival, its effect was not durable and 
most of the patients died of the disease. Moreover, response ratio 
of ipilimumab for in 60 patients with melanoma who became 
refractory to nivolumab was only 3.6%,26 whereas studies from 
Western countries report same figure to be 10 to 16%.27,28
Such unfavorable outcomes are found not only in the treat-
ment of patients with advanced stages of the disease but are 
also observed in the adjuvant setting. The CheckMate 238 
trial, a randomized phase 3 trial that evaluated the adjuvant 
use of nivolumab versus ipilimuamb,29 reported that patients 
with cutaneous melanoma (not including ALM and MCM) 
showed a 39% risk reduction; however, there was no statis-
tical clinical benefit of using nivolumab over ipilimumab 
for patients with ALM and MCM. Mutation burden has 
been reported to be associated with response to checkpoint 
F I G U R E  2  Kaplan‐Meier plots for 
each stages. (A) Survival curves for stage 
0, 1 and 2. (B) Survival curves for stage 3 
and 4
T A B L E  6  Factors associated with survival in all stages determined by Cox regression model (n = 2990)
 
Univariate analysis Multivariate analysis
HR 95% CI low 95% CI high P‐value HR 95% CI low 95% CI high P‐value
Age (cont) 1.004 0.998 1.009 0.203 1.01 1.004 1.016 0.001 21
Sex (male:0) 0.6194 0.5101 0.7521 0.000 001 0.8652 0.6652 1.125 0.280
T status (cont) 2.415 2.173 2.684 0.000 000 1.552 1.335 1.803 <0.000 00
Ulceration 3.438 2.811 4.206 <0.000 00 1.256 0.9344 1.689 0.131
Regression 1.567 1.031 2.38 0.0354 1.289 0.7783 2.134 0.324
Vitiligo 2.303 1.088 4.876 0.0293 1.954 0.7589 5.032 0.165
ALM (ref:SSM) 0.7244 0.597 0.8791 0.001 09 0.8605 0.6227 1.189 0.363
LMM (ref:SSM) 0.4259 0.2656 0.683 0.0004 0.5179 0.2216 1.211 0.129
NM (ref:SSM) 2.63 2.1 3.294 <0.000 00 1.379 0.9547 1.993 0.0867
Satellite/in‐transit 5.98 4.625 7.733 <0.000 00 1.025 0.6996 1.502 0.899
N status (cont) 2.602 2.402 2.818 <0.000 00 1.776 1.553 2.03 <0.000 00
Distant metastasis 11.83 9.444 14.82 <0.000 00 3.331 2.314 4.796 <0.000 00
ALM, acral lentiginous melanoma; CI, confidence interval; Cont, continuous variable; HR, hazard ratio; NC, not computable; N, nodal; ref, reference; SSM, superficial 
spreading melanoma, T, tumor thickness
Bold represents factors below P < 0.05 in multivariate analysis
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inhibitors30; tumors with a higher mutation burden respond 
to checkpoint inhibitors better than those with a lower mu-
tation burden. ALM and MCM are reported to have a lower 
mutation burden than other cutaneous melanoma,31 which 
supports the assertion that these clinical types have a lower 
response ratio than other types. Taken together, this accumu-
lated evidence suggests that ALM and MCM should perhaps 
be considered as “tough” types of melanoma and therefore 
require new treatment strategies that are especially designed 
for these clinical types.
The limitation of this study was the high number of pa-
tients whose follow up was lost. In this study, 465 out of 
4594 patients (10%) lost follow up and this might cause the 
bias toward better survival estimates as described in this 
review.32
In conclusion, through our analyses of 4594 patients, we 
were able to show the current trend of melanoma in Japan, 
and to the best of our knowledge, this is the largest dataset 
from an Asian country ever published. It is clear that mel-
anoma occurrence in Japan differs from that of Western 
F I G U R E  3  Kaplan‐Meier plots for 
Stage 3A‐3C. *P < 0.05
T A B L E  7  Factors associated with survival in stage IIIA determined by Cox regression model (n = 180)
 
Univariate analysis Multivariate analysis
HR 95% CI low 95% CI high P‐value HR 95% CI low 95% CI high P‐value
Age (cont) 0.995 0.972 1.02 0.686     
Sex (male: 0) 1.10 0.513 2.36 0.808     
T status (cont) 2.02 1.26 3.24 0.003 41 2.26 1.366 3.734 0.0015
Ulceration 0.805 0.109 5.96 0.831     
ALM (ref: SSM) 2.36 1.092 5.09 0.029 2.96 1.349 6.474 0.0068
LMM (ref: SSM) NC     
NM (ref: SSM) 1.37 0.58 3.25 0.471     
N2a (ref: N1a) 1.40 0.649 3.02 0.391     
ALM, acral lentiginous melanoma; CI, confidence interval; Cont, continuous variable; HR, hazard ratio; NA, not applicable; NC, not computable; ref, reference; SSM, 
superficial spreading melanoma
Bold represents factors below P < 0.05 in multivariate analysis
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countries in a number of respects, for example the high inci-
dence of ALM and MCM found in the Japanese population. 
We suggest conducting clinical trials to target these rare, but 
aggressive, types of melanoma.
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